menu
    • menu
    [{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"S-Pindolol Benzoate","moa":"\n5-HT1A receptor\/Beta-adrenoceptors\/Beta2-adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"S-Pindolol Benzoate","moa":"\n5-HT1A receptor\/Beta-adrenoceptors\/Beta2-adrenergic receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"S-Pindolol Benzoate","moa":"\n5-HT1A receptor\/Beta-adrenoceptors\/Beta2-adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"SCIRENT Clinical Research and Science d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"(S)-Pindolol Benzoate","moa":"5-HT1A receptor | beta-adrenoceptors | beta 2-adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Actimed Therapeutics \/ SCIRENT Clinical Research and Science d.o.o.","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ SCIRENT Clinical Research and Science d.o.o."},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ACM-001.1","moa":"5-HTA1a\/beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Actimed Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Actimed Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Actimed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Oxprenolol","moa":"Beta-2 adrenergic receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Actimed Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Actimed Therapeutics"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Oxprenolol","moa":"Beta-2 adrenergic receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oxprenolol","moa":"Beta-2 adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Faraday Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Oxprenolol","moa":"Beta-2 adrenergic receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Faraday Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Faraday Pharmaceuticals"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Pindolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"Pindolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pindolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Actimed Therapeutics

    Menu

    Actimed Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : (S)-Pindolol Benzoate

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : SCIRENT Clinical Research and Science d.o.o.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ACM-001.1 Effect On Lean Body Mass In Obese Patients During/Post Semaglutide Therapy

                            Details : (S)-Pindolol Benzoate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 03, 2025

                            Lead Product(s) : (S)-Pindolol Benzoate

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : SCIRENT Clinical Research and Science d.o.o.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S-Pindolol Benzoate

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Actimed to Study S-pindolol’s Muscle-Preserving Effects in Obese GLP-1 Patients

                            Details : Actimed is currently preparing for further clinical studies of its lead product ACM-001.1 (S-pindolol benzoate) which is an ACTA targeting multiple pathways that drive cancer cachexia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 20, 2025

                            Lead Product(s) : S-Pindolol Benzoate

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxprenolol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Actimed Therapeutics Granted FDA Orphan Drug Status for ALS Treatment ACM-002

                            Details : ACM-002 (S-oxprenolol) has demonstrated slowing disease progression, improvement in survival, attenuation of muscle loss, motor neuron protection in amyotrophic lateral sclerosis (ALS).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 04, 2024

                            Lead Product(s) : Oxprenolol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACM-001.1

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Quotient Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV...

                            Details : ACM-001.1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cachexia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 08, 2023

                            Lead Product(s) : ACM-001.1

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Quotient Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S-Pindolol Benzoate

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Actimed Therapeutics Announces FDA Approval of its Investigational New Drug Application for Phase 2b/3 IMPACT ...

                            Details : ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2/3 clinical data in cachexia associated with colorectal cancer (IMPACT CRC) and another in patients with non-small cell lung...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 07, 2023

                            Lead Product(s) : S-Pindolol Benzoate

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S-Pindolol Benzoate

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Mankind Pharma

                            Deal Size : $6.3 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Actimed Therapeutics Closes Over-Subscribed Series A Financing Round of £5 Million to Advance Clinical Develo...

                            Details : The investment will support the development of the Actimed pipeline, including ACM-001.1 (S-pindolol benzoate), with preparations under way for a Phase 2b/3 programme targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorect...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 26, 2023

                            Lead Product(s) : S-Pindolol Benzoate

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Mankind Pharma

                            Deal Size : $6.3 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pindolol

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Mankind Pharma

                            Deal Size : $12.1 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Actimed Therapeutics Successfully Closes Second Tranche Of £10m Seed Financing To Progress Pipeline For Treat...

                            Details : ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 04, 2023

                            Lead Product(s) : Pindolol

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Mankind Pharma

                            Deal Size : $12.1 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pindolol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio with Newly Granted US and Canadia...

                            Details : S-oxprenolol is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed and this newest patent completes the global patent estate relating to the treatment of ALS with S-oxprenolol.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 13, 2021

                            Lead Product(s) : Pindolol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pindolol

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $3.4 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Actimed Therapeutics Successfully Closed of £2.5m Extended Seed B Funding Round

                            Details : The proceeds will allow Actimed to further advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia, by performing a Pharmacokinetic (PK) and Pharmacodynamic (PD) study due to start later this year.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 10, 2021

                            Lead Product(s) : Pindolol

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $3.4 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actimed Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxprenolol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Faraday Pharmaceuticals

                            Deal Size : $134.7 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol

                            Details : Faraday gains global rights to develop and commercialize S-oxprenolol for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $2.7 million

                            April 13, 2021

                            Lead Product(s) : Oxprenolol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Faraday Pharmaceuticals

                            Deal Size : $134.7 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth